Okogen, Inc., a clinical-stage biotechnology company, announced on November 2, 2026, that the first patient has been dosed in the EMERALD Trial, a multicenter Phase 1/2 clinical study evaluating Treyegen (OKG-0303) for acute infectious conjunctivitis. The first dosing occurred at Ambade Eye Hospital in Nagpur, India. The full announcement is available online.
The start of patient dosing in EMERALD represents a significant clinical milestone for Treyegen, which is being developed as a single investigational ophthalmic therapy combining antiviral, antibacterial, and symptom-relieving mechanisms. Acute infectious conjunctivitis, commonly known as pink eye, is a condition where the underlying cause—whether viral or bacterial—is often unknown at the time of diagnosis. This diagnostic uncertainty can lead to inappropriate or delayed treatment. By targeting multiple pathways simultaneously, Treyegen aims to address this gap, potentially offering a more effective approach than current options that may be pathogen-specific.
The EMERALD Trial will assess safety, tolerability, clinical outcomes, and viral and bacterial activity. These endpoints are critical not only for Treyegen’s development but also for supporting the advancement of Okogen’s broader ranpirnase platform across multiple therapeutic areas. Ranpirnase is a host-directed antiviral agent, meaning it works by modulating the host’s immune response rather than directly targeting the virus. This mechanism could be particularly valuable against a wide range of viral pathogens and may reduce the likelihood of resistance.
Okogen’s strategy positions ophthalmology as the lead clinical proving ground for its ranpirnase platform, with the goal of applying clinical insights, formulation expertise, and manufacturing capabilities across a broader portfolio of antiviral therapies. The company is advancing ranpirnase-based therapies across four therapeutic pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. Success in the EMERALD Trial would not only validate Treyegen for conjunctivitis but also provide proof-of-concept for the platform’s potential in other indications. This could attract further investment and partnerships, accelerating the development of much-needed antiviral treatments.
For more information, visit www.okogen.com. The announcement includes forward-looking statements regarding the clinical development, potential benefits, and future regulatory progress of Treyegen and Okogen’s ranpirnase platform. These statements are subject to risks and uncertainties, including those related to clinical enrollment, study outcomes, regulatory requirements, manufacturing, and financing. Actual results may differ materially.
